Sponsors of CID Trials Should Discuss Plans With the FDA, Guidance Says

By Sam | December 16, 2020

Before proceeding with trials that use complex innovative designs (CID), sponsors should meet with the FDA to discuss their plans, according to a final guidance released Wednesday that provides details on the kinds of information to bring to an agency meeting.
Source: Drug Industry Daily

Posted in Drug Industry Daily